Gilead Sciences GILD Genvoya — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's genvoya — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's genvoya — total revenues?
- Gilead Sciences (GILD) reported genvoya — total revenues of $264M in Q1 2026.
- How has Gilead Sciences's genvoya — total revenues changed year-over-year?
- Gilead Sciences's genvoya — total revenues decreased by 27.5% year-over-year, from $364M to $264M.
- What is the long-term trend for Gilead Sciences's genvoya — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's genvoya — total revenues has grown at a -15.1% compound annual growth rate (CAGR), from $2.88B to $1.5B.
- What does genvoya — total revenues mean?
- The total revenue generated from sales of a specific HIV medication product.
- How do you interpret genvoya — total revenues?
- An increase in revenue signals strong market adoption, effective competitive positioning, or successful lifecycle management, while a decrease may indicate patent expiration, increased competition from generic or newer therapies, or shifting clinical treatment guidelines.
- How does genvoya — total revenues compare across companies?
- Comparable to product-specific revenue reporting in other major biopharmaceutical firms, often benchmarked against the revenue trajectories of competing branded therapies in the same therapeutic class.